2026-01-26 - Analysis Report
**Company Overview**
Eli Lilly and Company is a pharmaceutical and biotechnology company that discovers, develops, and markets medicines and health-related products.

**Return Rate Comparison**

* Review Stock (LLY): 661.99%
* S&P 500 (VOO): 126.41%
* Divergence: 530.90

The cumulative return of LLY is significantly higher than that of S&P 500, indicating a higher level of risk and potential reward.

**Alpha, Beta Analysis**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 46.0% | 14.2% | 34.0% | 0.7 | 103.7B |
| 2017-2019 | 54.0% | 12.1% | 29.0% | 0.7 | 117.8B |
| 2018-2020 | 82.0% | 19.7% | 57.0% | 0.7 | 151.4B |
| 2019-2021 | 128.0% | 19.7% | 63.0% | 0.7 | 247.6B |
| 2020-2022 | 169.0% | 19.7% | 163.0% | 0.7 | 328.0B |
| 2021-2023 | 259.0% | 18.2% | 238.0% | 0.5 | 522.6B |
| 2022-2024 | 349.0% | 23.9% | 320.0% | 0.6 | 692.1B |
| 2023-2025 | 454.0% | 33.4% | 378.0% | 0.7 | 963.4B |

The alpha and beta values indicate that LLY has generally outperformed the market, with a consistent and relatively stable beta value.

**Recent Stock Price Fluctuations**

* Close: $1,064.29
* Last-market: $1,064.29 (-2.12 from previous close)
* 5-day SMA: $1,061.98
* 20-day SMA: $1,070.25
* 60-day SMA: $1,025.50

The 5-day and 20-day SMAs are above the current close, indicating a short-term uptrend. However, the 60-day SMA is below the current close, indicating a longer-term downtrend.

**RSI, PPO Index Indicators, Risk Level**

* Market Risk Indicator (MRI): 0.70 (Medium Investment Recommended)
* RSI: 47.26
* PPO: -0.28
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium
* Recent relative divergence change: 3.90 (improving)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 0.00 (flat)
* Expected Return: 99.30% (expected excess return compared to S&P 500)

The RSI and PPO indicators suggest a moderate level of risk and potential for a buy signal.

**Recent News & Significant Events**

* [2026-01-23] Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
* [2026-01-21] Eli Lilly: Buy Ahead Of Its Earnings Day (Preview) (NYSE:LLY) - Seeking Alpha
* [2026-01-23] Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
* [2026-01-16] Buy The Dip In LLY Stock? - Forbes
* [2026-01-25] Eli Lilly and Company $LLY Shares Acquired by Kanawha Capital Management LLC - MarketBeat
* [2026-01-21] Why Eli Lilly (LLY) Stock Is Up Today - Finviz

These news events indicate a mix of positive and negative news, which may affect the stock price in the short term.

**Analyst Opinions**

* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
  - Opinions: 28
  - Target Price (avg/high/low): 1110.71 / 1500.00 / 770.00

The analyst opinions suggest a buy consensus with a target price above the current close.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|------|-----|---------|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |

The quarterly earnings data shows a significant increase in earnings per share (EPS) and revenue for the recent quarters.

**Financial Information - Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

The profit margin has remained relatively stable across the quarters.

**Financial Information - Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

The return on equity (ROE) ratio has fluctuated across the quarters.

**Comprehensive Analysis**

The comprehensive analysis suggests that Eli Lilly and Company has consistently outperformed the market, with a high degree of risk and potential reward. The recent earnings analysis shows a significant increase in earnings and revenue, while the financial information indicates a stable profit margin and fluctuating ROE ratio. The analyst opinions and recent news events suggest a mix of positive and negative news that may affect the stock price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.